The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GANX | -12.11% | N/A | N/A | -83% |
| S&P | +12.65% | +91.73% | +13.89% | +72% |
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.
No news articles found for Gain Therapeutics.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.02M | -8.4% |
| Market Cap | $53.90M | 133.3% |
| Market Cap / Employee | $2.16M | 0.0% |
| Employees | 25 | -21.9% |
| Net Income | -$5.81M | 28.7% |
| EBITDA | -$5.07M | 37.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $6.69M | -60.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.42M | -17.9% |
| Short Term Debt | $0.26M | -11.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -128.09% | -12.8% |
| Return On Invested Capital | -121.69% | -177.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5.10M | 11.8% |
| Operating Free Cash Flow | -$5.10M | 11.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.80 | 6.29 | 7.06 | 8.95 | 235.04% |
| Price to Sales | 958.95 | - | |||
| Price to Tangible Book Value | 3.85 | 6.41 | 7.19 | 9.15 | 235.81% |
| Enterprise Value to EBITDA | -8.10 | -14.77 | -10.65 | -9.59 | 824.59% |
| Return on Equity | -263.1% | -205.0% | -290.2% | -240.2% | 27.21% |
| Total Debt | $0.77M | $0.65M | $0.61M | $0.68M | -15.72% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
